Diabetes Obesity & Metabolism

Papers
(The H4-Index of Diabetes Obesity & Metabolism is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Diabetes, Obesity and Metabolism333
288
Issue Information222
Front Cover211
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study163
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?135
The effects of antihypertensive drugs on glucose metabolism118
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease112
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020112
Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized106
Development of the health economic model for type 2 diabetes considering glycaemic variability105
Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in typ101
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry93
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pum92
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis91
Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based 90
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis88
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy87
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”81
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes80
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study74
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic74
Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials72
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover71
Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice70
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’66
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin65
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐bli64
Adaptive bolus calculators for people with type 1 diabetes: A systematic review63
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes61
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes60
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar59
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh57
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis55
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status55
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Resul54
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial53
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study53
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia51
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study49
CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination48
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada48
Higher post‐prandial glucose excursions in youth with type 1 diabetes and celiac disease: Time to change the bolus?47
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial47
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c47
Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–201946
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy46
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial46
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic46
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial46
0.64400100708008